CORDIART™ is a unique ingredient developed by BioActor. It is a natural rutinoside extract from fruit, supporting healthy circulation. A clinical study has shown the beneficial effect of CORDIART™ on endothelial function, inflammatory status and metabolic parameters.
Cardiovascular health remains a major health concern. Consumers are getting increasingly aware of the importance of healthy arteries and the relevance of nutrition to support their cardiovascular health. CORDIART stimulates healthy blood flow. Hence clearly differentiating from generic ingredients in the cardiovascular category that mainly focus on cholesterol.
CORDIART™: A unique ingredient
CORDIART™ is the result of a strong partnership between its developer, BioActor, and its producer, Ferrer Healthtech. The result is a unique pharmaceutical grade rutinoside extract derived from citric fruit.
- Clinically proven health effects
- Known mode of action
- Low daily dose of 500 mg
- Superior bioavailability
- Patent pending
CORDIART™ is innovative and can be seamlessly integrated into functional foods, medical nutrition and dietary supplements supporting cardiovascular health.
Endothelial function: Key to cardiovascular health
Blood vessels are the interface between blood and body, and permit transport of nutrients to cells in the body. The inner lining of the blood vessel, the endothelium, plays a critical role in the maintenance of healthy arteries. With aging, lifestyle and inflammation, blood vessels become rigid. When the endothelium is not functioning properly, blood vessels lose the ability to fully dilate in response to a change in blood flow and attract more fat deposits and inflammatory cells, a state called endothelial dysfunction. Endothelial dysfunction is recognized as a major factor in the development of cardiovascular disease (CVD) like atherosclerosis, hypertension and heart failure.
Nitric Oxide (NO): protector of vascular health
Endothelial dysfunction is commonly associated with decreased Nitric Oxide (NO) bioavailability, due to impaired NO production by the endothelium. NO is a crucial molecule for the maintenance of vascular health. It largely mediates vasodilation, inhibition of inflammation and inhibition of platelet adherence and aggregation.
- Endothelial dysfunction is recognized as a major factor in the development of Cardiovascular disease (CVD) like atherosclerosis, hypertension and heart failure.
- Endothelial dysfunction is commonly associated with decreased Nitric Oxide (NO) bioavailability, due to impaired NO production by the endothelium
- NO is a crucial molecule for the maintenance of vascular health. It largely mediates vasodilation, inhibition of inflammation and inhibition of platelet adherence and aggregation.
- Improving endothelial function is key to maintain healthy artery function.
Mode of action
Mode of action
CORDIART™ activates the production of Nitric Oxide (NO) by the endothelium, which in turn sends a signal to the vascular smooth muscles to relax. This induces vasodilatation of the blood vessels and supports a healthy circulation. The beneficial effects of CORDIART™ on endothelial function are clinically proven.
More precisely, CORDIART™ stimulates eNOS activity and therefore helps to restore the physiological NO production. It is important to notice that this is more than just a temporary boost in NO levels as is generated with conventional NO boosting supplements or an attempt to boost NO levels using L-arginine. CORDIART™ enables the blood vessels to dilate on demand, the natural function is restored.
CORDIART™: Clinically proven
CORDIART™ has shown in a randomized placebo controlled trial (n=24) to significantly improve Flow Mediated Dilation (FMD), which is a direct marker of endothelial function. FMD is a measure of the capacity of the endothelium to respond to a change in blood flow, by means of vascular smooth muscle relaxation and vasodilatation.
Three weeks of intervention with 500 mg/day of CORDIART™ resulted in a better response of the arteries to changes in blood flow. Subjects who received 500 mg/day of CORDIART™ showed a 20% higher FMD-score compared to subjects who received a placebo. This results is clinically relevant as the treated group reached an FMD-score of >10, which is considered ‘healthy’, whilst the placebo group showed the hallmark of endothelial dysfunction. FMD scores of <10 are already sufficient to predict adverse cardiovascular events in otherwise healthy subjects. In addition, the concentrations of circulating inflammation markers hsCRP and SAA were reduced, which shows a reduction in inflammatory status. The levels of circulating E-selectin were also reduced, indicating less attraction of inflammatory cells to the endothelium.
CORDIART™ enhances endothelial function in humans and improves inflammatory status and metabolic parameters.
BioActor recently conducted a study to determine the bioavailability of CORDIART™ compared to a generic rutinoside extract. In a cross over study, 10 healthy subjects either received 500 mg of CORDIART™, or 500 mg of a generic rutinoside extract on separate days. After ingestion of the product, blood samples were taken at regular intervals during 24 hours and urine was collected. Results showed that CORDIART™ has a 50% higher bioavailability compared to generic rutinoside. Furthermore, CORDIART™ showed a faster and higher absorption into the blood during the first hour after ingestion.